Anti-tryptase antibodies, compositions thereof, and uses thereof
AssigneeGenentech, Inc.
InventorsXiaocheng CHEN, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
Life of this patent
Estimating the term…
Abstract
The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
Claims50
An isolated antibody that binds to human tryptase beta 1, or an antigen-binding fragment thereof, wherein the antibody comprises the following six hypervariable regions (HVRs):
- (a) an HVR-H1 comprising the amino acid sequence of DYGMV (SEQ ID NO:
- 7);
- (b) an HVR-H2 comprising the amino acid sequence of FISSGSSTVYYADTMKG (SEQ ID NO:
- 2);
- (c) an HVR-H3 comprising the amino acid sequence of RNYDDWYFDV (SEQ ID NO:
- 8);
- (d) an HVR-L1 comprising the amino acid sequence of SASSSVTYMY (SEQ ID NO:
- 4);
- (e) an HVR-L2 comprising the amino acid sequence of RTSDLAS (SEQ ID NO:
- 5);
- and
- (f) an HVR-L3 comprising the amino acid sequence of QHYHSYPLT (SEQ ID NO:
- 6).
2-12. (canceled)
An isolated antibody that binds to human tryptase beta 1, or an antigen-binding fragment thereof, wherein the antibody comprises the following six HVRs:
- (a) an HVR-H1 comprising the amino acid sequence of GYAIT (SEQ ID NO:
- 30);
- (b) an HVR-H2 comprising the amino acid sequence of GISSAATTFYSSWAKS (SEQ ID NO:
- 31);
- (c) an HVR-H3 comprising the amino acid sequence of DPRGYGAALDRLDL (SEQ ID NO:
- 32);
- (d) an HVR-L1 comprising the amino acid sequence of QSIKSVYNNRLG (SEQ ID NO:
- 33);
- (e) an HVR-L2 comprising the amino acid sequence of ETSILTS (SEQ ID NO:
- 34);
- and
- (f) an HVR-L3 comprising the amino acid sequence of AGGFDRSGDTT (SEQ ID NO:
- 35).
(canceled)
(canceled)
(canceled)
20-21. (canceled)
24-47. (canceled)
49-51. (canceled)
55-58. (canceled)
60-70. (canceled)
73-75. (canceled)
(canceled)
84-86. (canceled)
88-95. (canceled)
98-101. (canceled)
(canceled)
105-177. (canceled)
179-180. (canceled)
182-213. (canceled)
215-297. (canceled)
299-336. (canceled)
Dependencies are inferred from the claim text.